Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panitumumab in KRAS wild-type advanced pancreatic ductal adenocarcinoma
ACTRN12617000540314Phase 2Suspended
- Sponsor
- Dr Daniel Croagh
- Start
- Mar 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of panitumumab in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by Dr Daniel Croagh. Primary endpoint: Progression-free survival. Started Mar 2018; status: suspended.
02
Drugs
panitumumab
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on ACTRN12617000540314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12617000540314.